The Portable Neuromodulation Stimulator or PoNS™, developed by Helius Medical Technologies, is a non-invasive device that is designed to deliver neurostimulation through the tongue to treat balance disorders caused by mild to moderate Traumatic Brain Injury (mTBI). The device is intended to be used as part of targeted functional therapy called Cranial Nerve Non-Invasive Neuromodulation (CN-NINM) in combination with rehabilitation.
The PoNS™ is placed on the tongue, where it painlessly stimulates the tongue with electrical pulses. Stimulation of the trigeminal and facial nerves from the tongue delivers electrical signals directly into the brain stem and from there to the rest of the brain. The electrical stimulation is combined with physical, occupational, relaxation and cognitive exercises, based on the patient’s needs. For example, the patient may be instructed to run on a treadmill or stand on one leg for a period of time whilst undergoing the stimulation.
Abilify MyCite is a drug-device combination comprising aripiprazole embedded with an Ingestible Event Marker (IEM) sensor. The aripiprazole attaches in the brain to receptors which help normalise the activity of the brain. The drug is packaged within an innovative system which helps patients (and healthcare workers) monitor when the medication is taken through integration with a sensor patch and app. Abilify MyCite is different to other ways of monitoring whether medication has been taken because it gives results of the actual medication taken, without need for blood or urine samples, as opposed to an estimate and if licensed, will offer an additional treatment option for patients with BP1 and SCH.